Bleakley Financial Group LLC Raises Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Bleakley Financial Group LLC boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 35.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 68,352 shares of the company's stock after buying an additional 17,770 shares during the quarter. Bleakley Financial Group LLC's holdings in Kenvue were worth $1,459,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Choreo LLC boosted its holdings in Kenvue by 36.2% in the 4th quarter. Choreo LLC now owns 50,792 shares of the company's stock valued at $1,077,000 after purchasing an additional 13,506 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Kenvue by 38.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 406,467 shares of the company's stock valued at $8,677,000 after buying an additional 113,157 shares in the last quarter. Y.D. More Investments Ltd raised its stake in Kenvue by 15.7% during the fourth quarter. Y.D. More Investments Ltd now owns 6,513 shares of the company's stock worth $139,000 after acquiring an additional 882 shares in the last quarter. Stratos Wealth Partners LTD. lifted its holdings in shares of Kenvue by 4.7% during the fourth quarter. Stratos Wealth Partners LTD. now owns 13,461 shares of the company's stock valued at $287,000 after acquiring an additional 601 shares during the period. Finally, E. Ohman J or Asset Management AB acquired a new stake in shares of Kenvue in the 4th quarter valued at $1,793,000. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

NYSE:KVUE traded up $0.35 during mid-day trading on Tuesday, reaching $20.93. The stock had a trading volume of 10,921,780 shares, compared to its average volume of 12,761,109. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The stock has a market capitalization of $40.13 billion, a PE ratio of 39.49, a P/E/G ratio of 2.16 and a beta of 1.45. The stock has a 50-day simple moving average of $21.46 and a two-hundred day simple moving average of $22.02.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts anticipate that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.92%. Kenvue's payout ratio is 154.72%.

Analyst Ratings Changes

Several brokerages recently issued reports on KVUE. Barclays decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a report on Friday, January 17th. Piper Sandler raised shares of Kenvue from a "neutral" rating to an "overweight" rating and raised their price target for the company from $21.00 to $26.00 in a report on Monday, January 6th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and decreased their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Canaccord Genuity Group cut their price target on Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday. Finally, Citigroup lowered their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of "Hold" and an average price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.